Pharmaceuticals News and Research

RSS

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII.

8 Sep 2014

Non-invasive delivery of drugs for effective pain relief

Individuals who are squeamish about injections or are looking for a way to let collagen penetrate deeper into the skin may soon have a solution that is faster, more effective and painless.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

PDA launches one of two surveys on Quality Culture Metrics

The Parenteral Drug Association (PDA) today launched one of two surveys on Quality Culture Metrics as part of its continuing program to evaluate quality metrics that can inform the regulator's risk-based inspection programs.

8 Sep 2014

PHI collaborates with Northeastern University for establishing novel cell analysis applications

Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.

8 Sep 2014

Viewpoints: Rove renews attack on health law; Calif. 'vaccination crisis'

The disconnect between what Americans think of most provisions of Obamacare (love them!) and what they think of "Obamacare" (hate it!) has been the most perplexing aspect of rollout of the Affordable Care Act.

5 Sep 2014

Professor Bill Charman awarded FIP Lifetime Achievement Award in Pharmaceutical Sciences

The International Pharmaceutical Federation has honoured a prominent Monash scientist and Dean for his outstanding contribution to pharmaceutical sciences.

5 Sep 2014

New cancer drug renews debate about costs

The drug Opdivo, which went on sale in Japan this week, costs an average of $143,000 per patient, The Wall Street Journal reports.

5 Sep 2014

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

4 Sep 2014